ZCA
ALXN

Zeke Capital Advisors’s Alexion Pharmaceuticals ALXN Stock Holding History

Zeke Capital Advisors’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-2,429
Closed -$338K – 680
2018
Q3 		$338K Hold
2,429
– – 0.03% 494
2018
Q2 		$302K Sell
2,429
-3,232
-57% -$378K 0.03% 405
2018
Q1 		$631K Buy
+5,661
New +$677K 0.06% 282
2017
Q4 		– Sell
-3,751
Closed -$526K – 623
2017
Q3 		$526K Buy
+3,751
New +$510K 0.07% 213

Other funds holding ALXN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Zeke Capital Advisors's ALXN Position: Q4 2018 in Review

Zeke Capital Advisors sold out of Alexion Pharmaceuticals (ALXN) in Q4 2018, closing a stake of 2,429 shares — an estimated $338K sold.

Zeke Capital Advisors first reported a position in ALXN in Q3 2017 and held it in 4 quarters. The position peaked at $631K in Q1 2018. 608 funds tracked by Wall St. Rank hold ALXN as of Q4 2018.

  • Zeke Capital Advisors reported no remaining Alexion Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
  • Zeke Capital Advisors sold 2,429 Alexion Pharmaceuticals shares in Q4 2018, an estimated $338K.
  • Zeke Capital Advisors first reported a position in Alexion Pharmaceuticals in Q3 2017 and held it in 4 quarters.
  • Zeke Capital Advisors's Alexion Pharmaceuticals position peaked at $631K in Q1 2018.
  • 608 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q4 2018.

Based on Zeke Capital Advisors's 13F filing for Q4 2018, filed 11 Feb 2019.